Abstract
Background: Acute myeloid leukemia (AML) represents the largest number of annual deaths from hematologic malignancy. In the United States, it was estimated that 21.380 individuals would be diagnosed with AML and 49.5% of patients would die in 2017. Therefore, the search for novel compounds capable of increasing the overall survival rate to the treatment of AML cells is urgent.
Objectives: To investigate the cytotoxicity effect of the natural compound pomolic acid (PA) and to explore the mechanism of action of PA in AML cell lines with different phenotypes.
Methods: Three different AML cell lines, HL60, U937 and Kasumi-1 cells with different mechanisms of resistance were used to analyze the effect of PA on the cell cycle progression, on DNA intercalation and on human DNA topoisomerases (hTopo I and IIα) in vitro studies. Theoretical experiments of the inhibition of hTopo I and IIα were done to explore the binding modes of PA.
Results: PA reduced cell viability, induced cell death, increased sub-G0/G1 accumulation and activated caspases pathway in all cell lines, altered the cell cycle distribution and inhibited the catalytic activity of both human DNA topoisomerases.
Conclusion: Finally, this study showed that PA has powerful antitumor activity against AML cells, suggesting that this natural compound might be a potent antineoplastic agent to improve the treatment scheme of this neoplasm.
Keywords: Acute myeloid leukemia, natural compound, pomolic acid, human DNA topoisomerases, Topo I, Topo IIα, anticancer agent, drug discovery.
Anti-Cancer Agents in Medicinal Chemistry
Title:Antitumor Effect of Pomolic Acid in Acute Myeloid Leukemia Cells Involves Cell Death, Decreased Cell Growth and Topoisomerases Inhibition
Volume: 18 Issue: 10
Author(s): Michelle X.G. Pereira, Amanda S.O. Hammes, Flavia C. Vasconcelos, Aline R. Pozzo, Thaís H. Pereira, Ernesto R. Caffarena, Cerli R. Gattass and Raquel C. Maia*
Affiliation:
- Laboratorio de Hemato-Oncologia Celular e Molecular, Programa de Pesquisa em Hemato-Oncologia Molecular, Instituto Nacional de Cancer (INCA), Rio de Janeiro, (RJ),Brazil
Keywords: Acute myeloid leukemia, natural compound, pomolic acid, human DNA topoisomerases, Topo I, Topo IIα, anticancer agent, drug discovery.
Abstract: Background: Acute myeloid leukemia (AML) represents the largest number of annual deaths from hematologic malignancy. In the United States, it was estimated that 21.380 individuals would be diagnosed with AML and 49.5% of patients would die in 2017. Therefore, the search for novel compounds capable of increasing the overall survival rate to the treatment of AML cells is urgent.
Objectives: To investigate the cytotoxicity effect of the natural compound pomolic acid (PA) and to explore the mechanism of action of PA in AML cell lines with different phenotypes.
Methods: Three different AML cell lines, HL60, U937 and Kasumi-1 cells with different mechanisms of resistance were used to analyze the effect of PA on the cell cycle progression, on DNA intercalation and on human DNA topoisomerases (hTopo I and IIα) in vitro studies. Theoretical experiments of the inhibition of hTopo I and IIα were done to explore the binding modes of PA.
Results: PA reduced cell viability, induced cell death, increased sub-G0/G1 accumulation and activated caspases pathway in all cell lines, altered the cell cycle distribution and inhibited the catalytic activity of both human DNA topoisomerases.
Conclusion: Finally, this study showed that PA has powerful antitumor activity against AML cells, suggesting that this natural compound might be a potent antineoplastic agent to improve the treatment scheme of this neoplasm.
Export Options
About this article
Cite this article as:
Pereira X.G. Michelle , Hammes S.O. Amanda , Vasconcelos C. Flavia , Pozzo R. Aline , Pereira H. Thaís, Caffarena R. Ernesto , Gattass R. Cerli and Maia C. Raquel *, Antitumor Effect of Pomolic Acid in Acute Myeloid Leukemia Cells Involves Cell Death, Decreased Cell Growth and Topoisomerases Inhibition, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (10) . https://dx.doi.org/10.2174/1871520618666180412120128
DOI https://dx.doi.org/10.2174/1871520618666180412120128 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer
Current Cancer Drug Targets Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era
Current Cancer Drug Targets Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design Cyclodepsipeptides - Potential Drugs and Lead Compounds in the Drug Development Process
Current Medicinal Chemistry The Involvement of Blood Coagulation Factor XIII in Fibrinolysis and Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies
Current Pharmaceutical Design IL-6 Signaling and its Blockade with a Humanized Anti-Interleukin-6 Receptor Antibody in Rheumatoid Arthritis: Advent of a New and Innovative Therapeutic Drug, Tocilizumab
Current Rheumatology Reviews Phosphonomethoxyalkyl Analogs of Nucleotides
Current Pharmaceutical Design Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy Melanoma
Current Cancer Therapy Reviews The Price of the Successful Treatment of Pediatric Malignancies
Current Pediatric Reviews Novel Approaches for RNA Interference and their Application in Cancer Therapy
Current Pharmacogenomics Reactive Oxygen Species, Cancer and Anti-Cancer Therapies
Current Chemical Biology Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies
Mini-Reviews in Medicinal Chemistry Prevalence of Neuropathy Associated With Bortezomib: A Retrospective Study
Clinical Cancer Drugs Obesity and Cancer: Biological Links and Treatment Implications
Current Cancer Drug Targets Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia
Current Medicinal Chemistry Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry